Topics

Japan drug price reforms risk hurting investment: Bristol-Myers CEO

01:28 EDT 3 Oct 2019 | Reuters

Japan's "overly restrictive" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday.

Original Article: Japan drug price reforms risk hurting investment: Bristol-Myers CEO

NEXT ARTICLE

More From BioPortfolio on "Japan drug price reforms risk hurting investment: Bristol-Myers CEO"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...